{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:21:51Z","timestamp":1783052511904,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bbmt.2020.08.028","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T21:10:46Z","timestamp":1599081046000},"page":"2271-2278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed\/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions"],"prefix":"10.1016","volume":"26","author":[{"given":"Claire","family":"Burney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Wadhera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Breslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Alajangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Protheroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbmt.2020.08.028_bib0001","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation","volume":"14","author":"Milpied","year":"1996","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bbmt.2020.08.028_bib0002","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.1993.11.12.2342","article-title":"Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bbmt.2020.08.028_bib0003","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease","volume":"14","author":"Gajewski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.08.028_bib0004","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma","volume":"92","author":"Van Besien","year":"1998","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.bbmt.2020.08.028_bib0005","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","article-title":"Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data","volume":"10","author":"Chopra","year":"1992","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bbmt.2020.08.028_bib0006","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.bbmt.2020.08.028_bib0007","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"10.1016\/j.bbmt.2020.08.028_bib0008","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-2141.2000.01879.x","article-title":"Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure\u2010related toxicity","volume":"108","author":"Cull","year":"2000","journal-title":"BJHaem."},{"key":"10.1016\/j.bbmt.2020.08.028_bib0009","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bmt.1703898","article-title":"Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions","volume":"31","author":"Ho","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bbmt.2020.08.028_bib0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a010369","article-title":"Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma","volume":"10","author":"Przepiorka","year":"1999","journal-title":"Ann Oncol."},{"key":"10.1016\/j.bbmt.2020.08.028_bib0011","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.bbmt.2020.08.028_bib0012","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbmt.2014.11.673","article-title":"Carmustine, etoposide, cytarabine, and melphalan (BEAM)\u2013Campath allogeneic stem cell transplantation for aggressive non-Hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation","volume":"21","author":"Truelove","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.bbmt.2020.08.028_bib0013","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2014.03.005","article-title":"Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma","volume":"38","author":"Noreiga","year":"2014","journal-title":"Leukemia Res."},{"issue":"3","key":"10.1016\/j.bbmt.2020.08.028_bib0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/146532401753174034","article-title":"Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (\u00b1 fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion","volume":"3","author":"Lush RJ","year":"2001","journal-title":"Cytotherapy."},{"issue":"2","key":"10.1016\/j.bbmt.2020.08.028_bib0015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","article-title":"BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients","volume":"103","author":"Faulkner","year":"2004","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.bbmt.2020.08.028_bib0016","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/bjh.13073","volume":"168","author":"Clark","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.bbmt.2020.08.028_bib0017","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.10971","article-title":"Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation","volume":"92","author":"Mohty","year":"2007","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.bbmt.2020.08.028_bib0018","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2014","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.bbmt.2020.08.028_bib0019","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J Clin Oncol."},{"issue":"13","key":"10.1016\/j.bbmt.2020.08.028_bib0020","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.bbmt.2020.08.028_bib0021","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.bbmt.2020.08.028_bib0022","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.bmt.1705352","article-title":"Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and nonmyeloablative stem cell transplantation","volume":"37","author":"Miura","year":"2006","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"10.1016\/j.bbmt.2020.08.028_bib0023","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.23319","article-title":"Acute GVHD is a strong predictor of full donor CD3 T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation","volume":"87","author":"El-Cheikh","year":"2012","journal-title":"Am J Haematol."},{"issue":"10","key":"10.1016\/j.bbmt.2020.08.028_bib0024","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.bbmt.2008.07.013","article-title":"Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen","volume":"14","author":"Saito","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2020.08.028_bib0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2005.05372.x","article-title":"Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens","volume":"128","author":"Michallet","year":"2005","journal-title":"Br J Haematol."},{"issue":"23","key":"10.1016\/j.bbmt.2020.08.028_bib0026","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell\u2013depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2020.08.028_bib0027","unstructured":"Kings College Hospital NHS Trust. Prophylactic DLI for the prevention of relapse post HSCT in patients with high risk myeloid malignancy (PRO-DLI). 2020. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02856464. Accessed August 8, 2020."},{"issue":"5","key":"10.1016\/j.bbmt.2020.08.028_bib0028","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.leukres.2013.01.010","article-title":"Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant","volume":"37","author":"Nikolousis","year":"2013","journal-title":"Leukemia Res."},{"issue":"11","key":"10.1016\/j.bbmt.2020.08.028_bib0029","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3109\/10428190903200790","article-title":"Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence","volume":"50","author":"van Besien","year":"2009","journal-title":"Leukemia Lymphoma."},{"key":"10.1016\/j.bbmt.2020.08.028_bib0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/bmt.2010.55","article-title":"Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT","volume":"46","author":"Mickelson","year":"2011","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.bbmt.2020.08.028_bib0031","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol."}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120305437?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120305437?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:12:26Z","timestamp":1761059546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120305437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1083879120305437"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.028","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed\/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}